Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients : Is it an useful stewardship tool?
Copyright © 2021 Elsevier Inc. All rights reserved..
Ventilator associated pneumonia(VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin(PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analyzed. PCT levels greater than 0.975ng/mL were more related to VAP. No association was found for C-reactive protein (CRP). The results show that procalcitonin may be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal.
| Errataetall: |
ErratumIn: Diagn Microbiol Infect Dis. 2022 Aug;103(4):115698. - PMID 35688720 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 101(2021), 2 vom: 15. Okt., Seite 115344 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Côrtes, Marina Farrel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 14.09.2021 Date Revised 18.09.2023 published: Print-Electronic ErratumIn: Diagn Microbiol Infect Dis. 2022 Aug;103(4):115698. - PMID 35688720 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diagmicrobio.2021.115344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327890088 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327890088 | ||
| 003 | DE-627 | ||
| 005 | 20231225201800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2021.115344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327890088 | ||
| 035 | |a (NLM)34243136 | ||
| 035 | |a (PII)S0732-8893(21)00037-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Côrtes, Marina Farrel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients |b Is it an useful stewardship tool? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2021 | ||
| 500 | |a Date Revised 18.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Diagn Microbiol Infect Dis. 2022 Aug;103(4):115698. - PMID 35688720 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Ventilator associated pneumonia(VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin(PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analyzed. PCT levels greater than 0.975ng/mL were more related to VAP. No association was found for C-reactive protein (CRP). The results show that procalcitonin may be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Procalcitonin | |
| 650 | 4 | |a SARS-Cov-2 pandemic | |
| 650 | 4 | |a Secondary infection | |
| 650 | 4 | |a Ventilator Associated Pneumonia | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 700 | 1 | |a de Almeida, Bianca Leal |e verfasserin |4 aut | |
| 700 | 1 | |a Espinoza, Evelyn Patricia Sanchez |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Aléia Faustina |e verfasserin |4 aut | |
| 700 | 1 | |a do Nascimento Moura, Maria Luiza |e verfasserin |4 aut | |
| 700 | 1 | |a Salomão, Matias C |e verfasserin |4 aut | |
| 700 | 1 | |a Boszczowski, Icaro |e verfasserin |4 aut | |
| 700 | 1 | |a Freire, Maristela Pinheiro |e verfasserin |4 aut | |
| 700 | 1 | |a de Carvalho, Laina Bubach |e verfasserin |4 aut | |
| 700 | 1 | |a Paranhos-Baccalà, Gláucia |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Silvia Figueiredo |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, Thaís |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d 1986 |g 101(2021), 2 vom: 15. Okt., Seite 115344 |w (DE-627)NLM01262845X |x 1879-0070 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2021 |g number:2 |g day:15 |g month:10 |g pages:115344 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2021.115344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2021 |e 2 |b 15 |c 10 |h 115344 | ||